Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

Hepatology

Volumn 24, Issue 4 I, 1996, Pages 778-789

  Poynard, Thierry ^a,b   Leroy, Vincent ^a,b   Cohard, Marielle ^a,b   Thevenot, Thierry ^a,b   Mathurin, Philippe ^a,b   Opolon, Pierre ^a,b   Zarski, Jean Pierre ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON;

ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029833829     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008855176     Document Type: Article

References (100)

1. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991; 13:192-199.
2. Sacks HS, Berrier J, Reitman D, Angona-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. N Engl J Med 1987;19:450-455.
3. Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of medlars and manual methods. Control Clin Trials 1985;6:271-279.
4. DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Stat Med 1987;6:341-348.
5. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
6. Poynard T. Evaluation de la qualité méthodologique des essais thérapeutiques randomisés. Presse Med 1988;17:315-318.
7. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
8. Cimino L, Nardone G, Citarella C, Perna E, Capuano G, Budillon G. Treatment of chronic hepatitis C with recombinant interferon alfa. Ital J Gastroenterol 1991;23:399-402.
9. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa, a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
10. Giudici-Cipriani A, Rainisio C, Ponassi I, Rattenni S, Imberciadori G, Cavagnaro G, Marenco G. Terapia dell'epatite cronica non-A non-B con alfa-2b interferone. Studio clinico controllato e follow-up a lungo termine. Minerva Gastroenterologica E Dietologica 1991;37:85-90.
11. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, Coppere H, et al. Recombinant, human alpha interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. HEPATOLOGY 1991;13:393-397.
12. Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, Nakamura T, et al. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994;89:681-686.
13. Saracco G, Rosina F, Torrani-Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11(suppl 1):S43-S49.
14. Angelini G, Sgarbi D, Colombari R, Bezzi A, Castagnini A, De Berardinis F, Conti A, et al. Alpha-interferon treatment of chronic hepatitis C: a controlled, multicentre, prospective study. Digestion 1995;56:199-203.
15. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomised trial of lymphoblastoid alpha interferon in chronic hepatitis C effects on inflammation, fibrogenesis and viremia. J Hepatol 1993;17:390-396.
16. Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, Togger A, et al. Treatment of chronic hepatitis C with recombinant human interferon-2α: results of a randomized controlled clinical trial. HEPATOLOGY 1994;19:1-5.
17. Makris M, Preston FE, Triger DR, Underwood JCE, Westlake L, Adelman MI. A randomized controlled trial of recombinant interferon alpha in chronic hepatitis C in hemophiliacs. Blood 1991;78:1672-1677.
18. Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Minerio R, Sottili S, et al. Treatment of chronic sporadic-type non-A non-B hepatitis with lymphoblastoid interferon:gamma GT levels predictive for response. Dig Dis Sci 1994;39:866-870.
19. Rumi MG, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Zahm F, et al. Long-term titrated recombinant interferon-α2a in chronic hepatitis C: a randomized controlled trial. J Viral Hepat 1995;2: 73-76.
20. Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, Colambari R, et al. α-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol 1993;18:112-118.
21. Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreno V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha interferon in comparison with a control group. J Hepatol 1990; 11(suppl 1):S63-S67.
22. Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galliana F, Carreno V. High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C: a randomized controlled trial. HEPATOLOGY 1991;13:327-331.
23. Weiland O, Schvarcz R, Wejstal R, Norkrans G, Fryden A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol 1990;11(suppl 1):S57-S62.
24. De Conca V, Mornese A, Michetti P, Tricerri R, Mesiti S, Coccia G, Dodero M. Treatment of chronic NANB (type C) hepatitis with recombinant interferon alfa-2b. Preliminary clinical results [Abstract]. Gastroenterology 1990;98:A581.
25. Findor J, Perez V, Tanno H, Bruch-Igartua E, Villamil F, Fay O, Sorda J. Recombinant interferon alpha 2b in the treatment of chronic non A non B (NANB) hepatitis [Abstract]. HEPATOLOGY 1990;12:402.
26. Lin R, Schoeman M, Craig P, MacDonald J, Batey RG, Farell GC. Randomized controlled trial of interferon alpha-2b for chronic active hepatitis non A, non B: biochemical and histological evidence of remission [Abstract]. HEPATOLOGY 1989;10:646.
27. Perez R, Pravia R, Linares A, Gonzalez M, Rodriguez M, Lombrana JLS, Riestra S, et al. Treatment of chronic hepatitis C with interferon alfa-2b for 9 months [Abstract]. Gut 1993;34(suppl 2):139-40.
28. Carreño V, Trepo C, Gerken G, Barcena A, Bar Meir S, Desmet V, Ryff JC, et al. A double blind placebo controlled multicenter trial of treatment of chronic hepatitis NANB with recombinant interferon alpha-2a (Roferon-A) [Abstract]. HEPATOLOGY 1992;16:75A.
29. Cerini R, Cozzolino G, Morante R, Lucariello A, De Rosa ML, Cacciatore F. Relatively high dose for twelve months recombinant alfa interferon treatment in chronic C hepatitis: a randomized controlled study [Abstract]. HEPATOLOGY 1991;14:70A.
30. Ideo G, Bellati G, Pedraglio E, Leandro G. One year of therapy of non-A, non-B/C chronic hepatitis with recombinant alpha-2a interferon (r-IFN) or lymphoblastoid alpha interferon (1-IFN) [Abstract]. J Hepatol 1990;11(suppl 1):S31.
31. Castilla A, Camps-Bansell J, Civeira MP, Prietto J. Lymphoblastoid alpha interferon for chronic hepatitis C: a randomized controlled study. Am J Gastroenterol 1993;88:233-239.
32. David E, Pucci A, Palladia D, Saracco G, Garello E, Pintus C, Rocca G, et al. Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A, non-B viral hepatitis: a randomized controlled trial. Am J Clin Pathol 1992;98:397-401.
33. Manabe N, Chevalier M, Chossegros P, Causse X, Guerret S, Trépos C, Grimaud J-A. Interferon-α2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. HEPATOLOGY 1993;18:1344-1349.
34. Realdi G, Diodati G, Bonetti P, Scaccabarozi S, Alberti A, Ruol A. Recombinant human interferon alpha-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of randomized controlled trial. J Hepatol 1990;11(suppl 1):S68-S71.
35. Schvarcz R, Weiland O, Wejstal R, Norkrans G, Fryden A, Foberg U. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B post-transfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 1989; 21:617-625.
36. De Alava E, Camps J, Pardo-Mindan J, Garcia-Granero M, Munoz M, Sola J, Civeira MP, et al. Histological outcome of chronic hepatitis C treated with a 12-months course of lymphoblastoid interferon. Liver 1993;13:73-79.
37. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C, a randomized double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
38. Douglas DD, Rakela J, Lin HJ, Hollinger FB, Taswell HF, Czaja AJ, Gross J, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci 1993;38:601-607.
39. Kagawa T, Morizane T, Saito H, Miyaguchi S, Tsunematsu S, Tado S, Guevara FM, et al. A randomized controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol 1993;17:91-96.
40. Shindo M, Di Bisceglie A, Cheung L, Wai-Kuo Shih J, Cristiano K, Feinstone S, Hoofnagle JM. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115:700-704.
41. Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM, Thomas AC. Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis. BMJ 1989;298:80-82.
42. Kiyosawa K, Sodeyama T, Nakano Y, Yoda H, Tanaka E, Hayata T, Tsuchiya K, et al. Treatment of chronic non-A non-B hepatitis with human interferon beta: a preliminary study. Antiviral Res 1989;12:151-162.
43. Omata M, Ito Y, Yokosuka O, Imazeki F, Tagawa M, Takano S, Hosoda K, et al. Randomized double blind, placebo-controlled trial of eight-week course of recombinant alpha-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci 1991;36:1217-1222.
44. Taliani G, Furlan C, Grimaldi F, Clementi C, Lecce R, Manganoro M, Duca F, et al. One course versus two courses of recombinant alpha interferon in chronic C hepatitis. Arch Virol 1992;4(suppl):294-298.
45. Kakumu S, Arao M, Yashioka K, Hayashi H, Kurukabe A, Hirofuji H, Kowabe M. Recombinant human α-interferon therapy for chronic non-A, non-B hepatitis; second report. Am J Gastroenterol 1990;85:655-659.
46. Terronava R, Luca S. Treatment of chronic hepatitis C with recombinant interferon alpha-2b. J Chemother 1992;4:297-302.
47. Bosch O, Tapia L, Quiroga JA, Carreno V. An escalating dose regime of recombinant interferon-alpha 2a in the treatment of chronic hepatitis C. J Hepatol 1993;17:146-149.
48. Sieck JO, Ellis ME, Alfurayh O, Ali MA, Ali HA, Ayub A, Alfadda M, et al. Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study. J Hepatol 1993;19:418-423.
49. Liaw YF, Sheen IS, Lin SM, Chen TJ, Chu CM. Effects of orednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. Liver 1993;13:46-50.
50. Muller R, Baumgarten R, Markus R, Beckh K, Loeschke K, Stremmel, Niederau C, et al. Long-term treatment with low doses of interferon alfa-2b (rINFa2b) in patients with chonic non-A, non-B (NANB) hepatitis: data of a multicenter randomized prospectively controlled trial [Abstract]. J Hepatol 1990;11(suppl 2):S46.
51. Piazza M, Guadagnino V, Piccioto L, Borgia G, Orlando R, Abrescia N, Cianpi R, et al. Multicenter study on the treatment of chronic NANB hepatitis with recombinant human interferon alpha-2b [Abstract]. J Hepatol 1990;11(suppl 1):S163.
52. Bellati G, Boncinelli L, Colombo A, Alfieri G, Ideo G. A prospective randomized controlled trial of recombinant alpha interferon versus no treatment in non A, non B chronic active hepatitis (CAH): preliminary results [Abstract]. J Hepatol 1988;7(suppl 1):S95.
53. Tremolada F, Casarin C, Scaccabarozi S, Alberti A, Realdi G. Randomized controlled trial of recombinant alpha-2a interferon in chronic NANB post-transfusion hepatitis. [Abstract]. J Hepatol 1990;11(suppl 1):S117.
54. Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, Cavalletto D, et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993;17(suppl 3):S123-S126.
55. Hagiwara H, Hayashi N, Mita E, Takahara T, Kasahara A, Fusamoto H, Kamoda T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-883.
56. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamira K. A controlled study to determine the optimal dose regimen of interferon-α 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-1249.
57. Lin R, Roach E, Zimmerman M, Strasser S, Farrel G. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995;23:487-496.
58. Picciotto A, Callea F, Varagona G, Bardellini E, Borzone S, De Conca V, Vallarino E, et al. High-dose interferon therapy in patients with chronic hepatitis C: biochemical virological and histological evaluation of two different doses. Liver 1995;15:20-24.
59. Caporaso N, Suozzo R, Morisco F, D'antonio M, Romano M, Coltorti M. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol 1993;25:482-486.
60. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. HEPATOLOGY 1995;22:700-706.
61. Enriquez J, Torras X, Miralles F, Martinez Cerezo FJ, Sancho Poch FJ, Buenestado J, Mados P, et al. Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viremia and histological activity. J Viral Hepat 1995;2:181-187.
62. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-165.
63. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-α2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994;39:1273-1280.
64. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM, Le groupe français pour l'étude du traitement des hépatites chroniques NANB/C. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994;106:686-690.
65. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trépo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-1462.
66. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, et al. Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α2b. HEPATOLOGY 1993;18: 1300-1305.
67. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. HEPATOLOGY 1995;21:291-297.
68. Bellobuono A, Mondazzi L, Tempini S, Bellati G, Cassara L, Lombino M, Silini E, et al. Efficacy of different regimens of alpha interferon in chronic hepatitis C and relationship between response and HCV genotype [Abstract]. J Hepatol 1994;21(suppl):S35.
69. Brouwer JT, Kleter GEM, Nevens F, Fevery J, Elewaut A, Versieck J, Adler M, et al. Benelux multicenter trial of alpha interferon treatment for chronic hepatitis C: standard vs high-dose therapy monitored by biochemical and virologic markers (interim analysis) [Abstract]. Gut 1993; 34(suppl):S119-S120.
70. Casarin C, Chemello L, Bonetti P, Pontisso P, Alberti A, the TVVH study groups. Treatment of chronic hepatitis C with different doses and types of interferon alpha (IFN): a comparative study [Abstract]. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo, Japan: Springer-Verlag; 1993:245.
71. Ouzan D, Skaf R, Andréani T, Opolon P, Trépo C. French multicenter controlled trial of interferon alpha-2a in chronic hepatitis C. Michel H, Couzigou P. Does an attack dose (6 MU) increase the response rate at 6 and 12 months [Abstract]. J Hepatol 1993;18:853.
72. Ascione A, De Luca M, Canestrini C, Amitrano L, Gigliotti T, Addario L, Sergio A, et al. Three versus six MU interferon (IFN) alpha 2b in the therapy of HCV-related chronic liver disease: randomized multicenter study [Abstract]. HEPATOLOGY 1994;20:155A.
73. Cerini R, Cozzolino G, Morante R, Lucariello A, De Rosa ML, Cacciatore F. Relatively high dose for twelve months recombinant alfa interferon treatment in chronic C hepatitis: a randomized controlled study [Abstract]. HEPATOLOGY 1991;16:70A.
74. Felaco FM, Piccinino F, Messina V, Aprea L, Piccinino R, Pasquale G, Sagnelli E, et al. Lymphoblastoid interferon (IFN) treatment of HCV chronic hepatitis, evaluation of three different doses. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo, Japan: Springer-Verlag; 1993:245.
75. Milella M, Santantonio T, Monno L, Pastore G. Comparison of short vs long-term treatment with recombinant alpha interferon in chronic hepatitis C [Abstract]. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo, Japan: Springer-Verlag; 1993: 245.
76. Craxi A, Di Marco V, Lo Iacono O, Almasio P, Bruno R, Gamma C, Fiorello F, et al. Lymphoblastoid alpha-interferon for post-transfusion chronic hepatitis C: a randomized trial of 6 vs 12 months treatment [Abstract]. J Hepatol 1992;16(suppl 1):S8.
77. Areias J, Pedroto I, Freitas T, Cerqueira R, Teixeira R, Pinho L, Justica B, et al. Three versus five million units interferon recombinant α2b in the treatment of chronic hepatitis C: a randomized study [Abstract]. HEPATOLOGY 1995;22:115A.
78. Lino S, Hino K, Kuroki T, Susuki H, Yamamoto S. Treatment of chronic hepatitis C with high dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993;38:612-618.
79. Polus M. L'interferon alpha 2b recombinant dans le traitement de l'hépatite chronique virale C: comparaison de deux schémas, classique et à hautes doses. Rev Med Liege 1995;50:226-229.
80. Budillon G, Cimino L, Del Vecchio Blanco C, Mazzacca G, Iaquinto G, D'Ascoli B, Lompasi F, et al. Long-term follow-up evaluation in HCV chronic hepatitis treated with alpha-2b interferon. a comparison of two protocols. Ital J Gastroenterol 1994;26:16-20.
81. Nakajima H, Yamauchi M, Hirakawa J, Nakahara M, Ohata M, Mizuhara Y, Toda G, et al. Treatment of chronic active hepatitis C with different regimens of interferon alpha-2a (IFN-2a) [Abstract]. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo, Japan: Springer-Verlag; 1993:244.
82. Takeda T, Kuroki T, Fukuda K, Yabusako T, Nishiguchi S, Nakajima S, Shiomi F, et al. A long-term therapeutic efficacy of interferon for patients with chronic hepatitis C. Nippon Shokakibyo Gakkai Zasshi. Japanese Journal of Gastroenterology 1993;28(suppl 5):104-108.
83. Varagona G, Brown D, Kibbler H, Scheuer P, Ashrafzabeh P, Sherlock S, McIntyre N, et al. Response, relapse and re-treatment rats and viraemia in chronic hepatitis C treated with alpha2b interferon: a phase III study. Eur J Gastroenterol 1992;4:707-712.
84. Rakela J, Tong M, Shiffman M, Wright T, Hollinger FB, Fawaz K, Jacobson I, et al. An open-label, randomized, parallel evaluation of one, three, and six million units of interferon (IFN) alfa-2a in the six-month treatment of patients with chronic non-A, non-B hepatitis (NANB). [Abstract]. Gastroenterology 1992;104:A976.
85. De Bac C, Grimaldi F, Clementi C, Duca F, Livoli D, Taliani G. Efficacy of different regimens of interferon alpha-2b treatment in chronic hepatitis C [Abstract]. Gut 1993;34(suppl 1):S135.
86. Garcia-Buey L, Garcia-Monzon C, Garcia-Sanchez A, Pajares JM, Moreno-Otero R. Treatment of chronic NANB viral hepatitis with recombinant interferon alfa-2b. preliminary clinical and immunologic results. J Hepatol 1990;11(suppl 1):S158.
87. Lindsay KL, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag J, Perrillo R, et al. Long-term response to higher doses of interferon (IFN) alfa-2b treatment of patients with chronic hepatitis C: a randomized trial [Abstract]. HEPATOLOGY 1993;18:106A.
88. Negro F, Baldi M, Mondardini A, Ballare M, Capalbo M, Chiaberge E, Abate ML, et al. Continuous vs intermittent administration of alpha-interferon in chronic hepatitis C [Abstract]. J Hepatol 1992;16(suppl 1): S48.
89. Torras J, Martinez-Cerezo FJ, Enriquez J, Buenestado J, Puig M, Boadas J, Portorreal R, et al. Lymphoblastoid interferon in chronic hepatitis C: preliminary results of two dosages regimens [Abstract]. J Hepatol 1992; 16(suppl 1):S50.
90. Alberti A, Chemello L, Belussi F, Pontisso P, Tisminetzky S, Gerotto M, et al. Outcome of acute hepatitis C and role of alpha interferon therapy. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo, Japan: Springer-Verlag; 1994:604-660.
91. Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D, Colombo M. A multicenter randomized controlled trial of recombinant interferon alpha-2b in patients with acute transfusion-associated hepatitis C. HEPATOLOGY 1994;19:19-22.
92. Takano S, Satomura Y, Omata M, Japan Acute Hepatitis Cooperative Study Group. Effect of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Gastroenterology 1994; 107:805-811.
93. Viladomiu L, Genescà J, Esteban JI, Allende H, Gonzàlez A, López-Talavera JC, Esteban R, et al. Interferon-alpha in acute post transfusion hepatitis C: a randomized, controlled trial. HEPATOLOGY 1992;15:767-769.
94. Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon α-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994;21:861-866.
95. Tassopoulos NC, Koutelou MG, Papatheodoridis G, Polychronaki H, Delladetsima I, Giannikakis T, Todoulos A, et al. Recombinant human interferon alpha-2b treatment for acute non-A, non-B hepatitis. Gut 1993; 34(suppl 2):S130-S132.
96. Esteban R. Is there a role for interferon in acute viral hepatitis? Gut 1993;34(suppl):S77-S80.
97. Colombo M, Lampertico P, Rumi M. Multicentre randomised controlled trial of recombinant interferon alpha-2b in patients with acute non-A, non-B/type C after transfusion. Gut 1993;34(suppl):S141.
98. Malaguarnera M, Restuccia S, Trovato G, Siciliano R, Motta M, Trovato BA. Interferon-α treatment in patients with chronic hepatitis C. A meta-analytic evaluation. Clin Drug Invest 1995;9:141-149.
99. Bardelli F, Messori A, Rampazzo R, Alberti A, Martini N. Effect of recombinant or lymphoblastoid interferon-α on alanine aminotransferase in patients with chronic hepatitis C or chronic non-A non-B hepatitis. A meta-analysis. Clin Drug Invest 1995;9:239-254.
100. Bedossa P, the French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994;20:15-20.